For example, administration of SCFAs can decrease the lipid accumulation in the liver of animal models of obesity and T2DM, via increasing hepatic AMPK phosphorylation and expression of PPARα, and further stimulating FFA oxidation (8–10). This evidence concerns the gene PPARA and obesity disorder.